APA (7th ed.) Citation

Mills, M. N., Uno, A., Li, P., Liveringhouse, C., Kim, Y., Oliver, D. E., . . . Ahmed, K. A. (2024). Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone. Clinical lung cancer, 25(5), 417-423.e1. https://doi.org/10.1016/j.cllc.2024.04.005

Chicago Style (17th ed.) Citation

Mills, Matthew N., et al. "Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone." Clinical Lung Cancer 25, no. 5 (2024): 417-423.e1. https://doi.org/10.1016/j.cllc.2024.04.005.

MLA (9th ed.) Citation

Mills, Matthew N., et al. "Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone." Clinical Lung Cancer, vol. 25, no. 5, 2024, pp. 417-423.e1, https://doi.org/10.1016/j.cllc.2024.04.005.